Portage Biotech Stock Surges As It Prepares For Human Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Should l Buy ?
Source: Benzinga
Stock Performance: Portage Biotech Inc. (PRTG) saw a significant increase in stock price, rising 42.3% to $12.03 during premarket trading, with a session volume of 4.49 million shares compared to the average of 1.2 million.
Research Developments: The company reported promising preclinical efficacy data for its selective adenosine A2B receptor inhibitor, PORT-7, which showed superior tumor growth inhibition when combined with an anti-PD1 antibody in a murine mesothelioma model, and plans to initiate a first-in-human clinical trial.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
